|Day Low/High||0.04 / 0.05|
|52 Wk Low/High||0.01 / 0.10|
The biotech company halts or slows some development spending to preserve capital.
An imbalance of death rates prompts it to end the trial of lead investigational cancer therapy Ascentar.
Emergent BioSolutions gains on a $448 million contract for its anthrax vaccine BioThrax.
This week, questions on Vertex Pharmaceuticals, Novacea and more.
The mailbag returns with questions about Northwest Biotherapeutics, Flamel and, of course, Dendreon.
Novacea's fair value, company-to-watch Amicus Therapeutics and just a little more Dendreon.
The Novacea story, Millenium Pharmaceuticals potential and Satraplatin's impact.
This environment offered good opportunities for day trades but was an invitation to lose money on everything else.
Early weakness is met by hearty buying after the FOMC minutes. Gallatin's Mark Keller talks bubbles vs. bull markets. Plus, 'Should I Buy It?'
Early weakness is met by hearty buying after the FOMC minutes. Gallatin's Mark Keller talks private equity, plus 'Should I Buy It?'.
Shares of the drugmaker double on news of a development and marketing deal for its Asentar.
Johnson & Johnson's rise on better-than-expected earnings boosted health care stocks.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.